Projected Income Statement: Lineage Cell Therapeutics, Inc.

Forecast Balance Sheet: Lineage Cell Therapeutics, Inc.

Forecast Balance Sheet - Lineage Cell Therapeutics, Inc.
Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027 2028
Net Debt - - - - - - - -
Change - - - - - - - -
Announcement Date 3/10/22 3/9/23 3/7/24 3/10/25 3/5/26 - - -
Estimates

Cash Flow Forecast: Lineage Cell Therapeutics, Inc.

Fiscal Period: December 2022 2023 2024 2025 2026 2027 2028
CAPEX 1 0.413 0.674 0.565 0.522 - 0.4 1
Change - 63.2% -16.17% -7.61% -100% - 150%
Free Cash Flow (FCF) 1 0.646 -29.24 -23.66 -19.44 -27 -9.35 3.1
Change - -4,626.32% 19.09% 17.82% -38.88% 65.37% 133.16%
Announcement Date 3/9/23 3/7/24 3/10/25 3/5/26 - - -
1USD in Million
Estimates

Forecast Financial Ratios: Lineage Cell Therapeutics, Inc.

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026 2027 2028

Profitability

         
EBITDA Margin (%) - -1,113.52% -148.22% -268.76% -219.7% -246.77% -554.96% -130.38% -48.12%
EBIT Margin (%) - -1,133.63% -153.17% -276.5% -226.11% -251.57% -289.12% -155.52% 13.99%
EBT Margin (%) - -996.77% -175.56% -260.28% -195.62% -471.61% -297.54% -149.55% 18.12%
Net margin (%) - -990.99% -178.69% -240.2% -195.9% -436.47% -303.77% -149.66% 18.11%
FCF margin (%) - - 4.39% -326.89% -249.05% -133.56% -477.27% -43.83% 5.21%
FCF / Net Income (%) - - -2.46% 136.09% 127.13% 30.6% 157.11% 29.28% 28.78%

Profitability

         
ROA -13.79% -21.78% -9.44% -11.8% -12.53% -12.06% - - -
ROE -20.05% -46.52% -32.37% -32.07% -26.73% -105.3% - - -

Financial Health

         
Leverage (Debt/EBITDA) - - - - - - - - -
Debt / Free cash flow - - - - - - - - -

Capital Intensity

         
CAPEX / Current Assets (%) - - 2.81% 7.53% 5.95% 3.59% - 1.88% 1.68%
CAPEX / EBITDA (%) - - -1.9% -2.8% -2.71% -1.45% - -1.44% -3.49%
CAPEX / FCF (%) - - 63.93% -2.31% -2.39% -2.69% - -4.28% 32.26%

Items per share

         
Cash flow per share 1 - - - - - - - - -
Change - - - - - - - - -
Dividend per Share 1 - - - - - - - - -
Change - - - - - - - - -
Book Value Per Share 1 - - - - - - - - -
Change - - - - - - - - -
EPS 1 - -0.26 -0.15 -0.12 -0.09 -0.28 -0.0514 -0.1033 0.0383
Change - - 42.31% 20% 25% -211.11% 81.63% -100.91% 137.09%
Nbr of stocks (in thousands) - 168,558 169,976 174,987 220,416 242,328 255,155 255,155 255,155
Announcement Date - 3/10/22 3/9/23 3/7/24 3/10/25 3/5/26 - - -
1USD
Estimates
2026 *2027 *
P/E -15.9x -7.9x
PBR - -
EV / Sales 36.8x 9.76x
Yield - -

EPS & Dividend

EPS & Dividend - Lineage Cell Therapeutics, Inc.


Y-o-Y evolution of P/E

Valuation ratios - P/E - Lineage Cell Therapeutics, Inc.
 
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Lineage Cell Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
0.8158USD
Average target price
5.500USD
Spread / Average Target
+574.18%
  1. Stock Market
  2. Stocks
  3. LCTX Stock
  4. Financials Lineage Cell Therapeutics, Inc.